Neurocrine Biosciences | Fremdkapital



Loan Capital Veränderung Datum
AbbVie USD 60.34B 1.83B 2024-12
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
ALKERMES USD 0 285.82M 2024-12
Alnylam Pharmaceuticals USD 1.02B 967K 2024-12
Amgen USD 56.55B 305M 2024-12
Biogen USD 4.55B 1.4M 2024-12
BioMarin Pharmaceutical USD 595.89M 1.27M 2024-12
Cytokinetics USD 645.6M 1.1M 2024-12
Dynavax Technologies USD 223.85M 293K 2024-12
Exelixis USD 0 0 2025-01
Gilead Sciences USD 24.9B 3.46B 2024-12
Halozyme Therapeutics USD 1.51B 1.64M 2024-12
Incyte USD 33.54M 5.32M 2024-12
Intra Cellular Therapies USD 0 0 2024-12
Ionis Pharmaceuticals USD 1.25B 11.67M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Pfizer USD 57.4B 597M 2024-12
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 2.7B 720.4M 2024-12
Repligen USD 521.61M 3.89M 2024-09
Sarepta Therapeutics USD 1.14B 1.16M 2024-12
Teva Pharmaceutical Industries USD 16B 398M 2024-12
Ultragenyx Pharmaceutical USD 0 0 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Neurocrine Biosciences Fremdkapital - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.